South America’s drug patent landscape is often treated like a black box—until you’re the one trying to launch, defend, or challenge a product in-market.
Here’s the agitation: most teams don’t realize how quickly strategy can go sideways when they assum…

Most 505(b)(2) strategies fail before the first filing—because the real competition isn’t the science. It’s the business model.
If you’re a CDMO, specialty lab, or service provider supporting 505(b)(2) follow-on drugs, you already know the pitch: faste…

Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/

Pharma doesn’t just defend patents anymore. It builds a fortress.
For years, the public debate has focused on a familiar villain: the “evergreening” patent strategy—filing new patents around old drugs to delay generic competition. But the more conseque…

India’s Drug Patent Clock: The “How Long” Question Everyone Gets Wrong
In pharma, timing is everything—especially when it comes to patents.
But here’s the uncomfortable truth: when people ask, “How long does a drug patent last in India?” they often mea…

The Generic Drug Race Is Not a Sprint—It’s a Chess Match. Here’s Why Paragraph IV Still Moves Markets.
If you think the generic drug business is just about filing paperwork and waiting for approvals, you’re missing the real game: patent litigation stra…

Biopharma’s “patent cliff” isn’t just a legal event—it’s a commercial deadline.
If you’re a biopharma commercial, market access, or business development vendor, the window to win EU tenders before patent expiry is narrower than most teams realize—and…

Biopharma talent is moving—fast—and the next destination isn’t just “more science.” It’s the legal and regulatory front lines where science becomes strategy.
That’s the subtext of the latest wave of biosimilar patent wars, and it’s showing up in how co…

Specialty pharmacy contracts are the new patent cliff. Here’s how biopharma teams can win before the exclusivity window closes.
The patent expiration calendar is familiar to every biopharma operator. But the real commercial inflection point often arriv…

Can This Drug Do That? The Internet Keeps Asking. The Pharmacology Keeps Sighing.
Every day, someone somewhere posts the same question in a new outfit: “Can this drug treat X?” Or: “What about using it for Y?” It’s a fair question—especially in a world…